Published June 13, 2024 | Version 1
Journal Open

Tumor-Specific Immunity: The Promise of Cancer Vaccines

  • 1. Resident Intern, Government Medical College and Hospital, Aurangabad (Maharashtra)
  • 2. Undergraduate Medical Student, Institute of Medical Sciences and SUM Hospital, (Siksha 'O' 3 Anusandhan University) Bhubaneshwar (Odisha)
  • 3. Department of Oral Pathology, People's College of Dental Sciences & Research Centre, Bhopal (Madhya Pradesh)

Description

ABSTRACT: 
    Cancer vaccines are a potentially effective way to improve the effectiveness of cancer immunotherapy. 
They are designed to elicit tumor-specific cellular immunity by antigen presentation by dendritic cells. 
Tumor-associated antigens (TAAs) have been given top priority by the National Cancer Institute as 
targets for cancer vaccines. AIA stands for "Adoptive Immune Activation." This approach involves 
transferring immune cells that have been activated and expanded outside the body back into the patient 
to target and eliminate cancer cells. The AIA took into account a number of parameters, including 
therapeutic efficacy, immunogenicity, carcinogenicity, specificity, expression level, and positive cell 
rate. The spectrum of cancer vaccines is delved in this paper, which covers their creation, modes of 
action, clinical uses, and future directions.

Files

Dr Sumedh with QR code.pdf

Files (643.3 kB)

Name Size Download all
md5:33964b0dbca6c5493927497793c36507
643.3 kB Preview Download

Additional details

Dates

Accepted
2024-05-26

References

  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8. PMID: 30620402.
  • 2. Sa Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018 Mar 23;359 (6382):1355-1360. doi: 10.1126/science.aar 7112. PMID: 29567706.
  • 3. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer. 2006 Mar;6(3):204-16. doi: 10.1038/nrc1815. PMID: 16498443.
  • 4. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078- 0432.CCR-09-0737. PMID: 19723653; PMCID: PMC5779623.
  • 5. Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. PMID: 26214521; PMCID: PMC4588240.
  • 6. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013 Jul 25;39(1):38-48. doi: 10.1016/j.immuni.2013.07.004. PMID: 23890062; PMCID: PMC3788678.
  • 7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. PMID: 20818862.
  • 8. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015 May 15;348(6236):803-8. doi: 10.1126/science.aaa3828. Epub 2015 Apr 2. PMID: 25837513; PMCID: PMC4549796.